Follicular Lymphoma
Conditions
Brief summary
Lenalidomide Based Immunotherapy in the Treatment of FL
Detailed description
Lenalidomide Based Immunotherapy efficacy related molecular biomarker in follicular lymphoma
Interventions
DRUGRevlimid
Revlimid 25mg PO d1-10 Plus Rituximab 375 mg/m2 IV d0
Sponsors
Ruijin Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
16 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
Patients diagnose as de novo or relapse refractory FL grade 1-3A . No history of stem cell transplantation. Written informed consent.
Exclusion criteria
Chemotherapy or large field radiotherapy within 3 weeks prior to entering the study. Clinically significant active infection. Impaired liver, renal or other organ function not caused by lymphoma, which will interfere with the treatment schedule. Any significant medical or psychiatric condition that might prevent the patient from complying with all study procedures. Subject has ≥grade 2 peripheral neuropathy or grade 1 with pain within 14 days before enrollment. Patients who are pregnant or breast-feeding. HIV infection.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| CR | 12 weeks | Complete response rate |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PFS | 1 year | Progression free survival rate |
| OS | 1 year | Overall survival rate |
| ORR | 12 weeks | Overall response rate |
Countries
China
Contacts
Primary ContactWeili Zhao
Outcome results
None listed